<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03853486</url>
  </required_header>
  <id_info>
    <org_study_id>ATHN 9</org_study_id>
    <nct_id>NCT03853486</nct_id>
  </id_info>
  <brief_title>ATHN 9: Severe VWD Natural History Study</brief_title>
  <official_title>ATHN 9: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Severe Von Willebrand Disease (VWD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Thrombosis and Hemostasis Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>American Thrombosis and Hemostasis Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ATHN 9 is a natural history study to assess the safety of various Von Willebrand Factor (VWF)
      regimens for different indications (on-demand, surgery and prophylaxis) in adult and
      pediatric participants with clinically severe congenital VWD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overarching objective of this longitudinal, observational and prospective study is to
      characterize the safety and effectiveness of factor replacement in participants with
      clinically severe congenital VWD (VWF:Ag, VWF:GPlbM or VWF:RCo of ≤30% or ≤40% of normal with
      severe bleeding phenotype defined as requiring recurrent use of factor concentrates) enrolled
      in the ATHNdataset.

      This is a longitudinal, observational cohort study being conducted at up to 30
      ATHN-affiliated sites. Participants will be followed for 2 years from time of study
      enrolment. The total study duration is 3 years.

      Safety will be measured by the number of reported events defined by the European Haemophilia
      Safety Surveillance (EUHASS) program. In addition, although not specifically defined by
      EUHASS, treatment-emergent side effects of therapy will be included as reportable events
      including: hypersensitivity/allergic reactions, thrombotic events, VW Factor inhibitor
      development, treatment-emergent side effects of therapy, transfusion-transmitted infections,
      malignancy, cardiovascular events, neurological events, unexpected poor efficacy and death.

      Secondary objectives of ATHN 9 are:

        -  to enrich and analyze the data from currently enrolled participants with clinically
           severe congenital VWD in the ATHNdataset via the collection of laboratory data
           consisting of a standardized diagnostic battery using an ELISA based VWF activity assay,
           and genetic sequence analysis of VWF coding regions and adjacent non-coding regions;

        -  to establish a platform for sub-studies for participants with congenital severe VWD,
           that are treated with VWF products on demand or have started on or switched to a
           particular VWF containing product for prophylaxis;

        -  to evaluate the use of factor replacement as prophylaxis in participants over 6-month
           time periods;

        -  to describe bleeding events, changes in overall bleeding and annualized bleeding rate
           (ABR) over the course of the study as measured by individual bleeding components; and

        -  to describe real-world effectiveness of VWD treatment as measured by health care
           utilization and quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reported adverse events from VWF regimens for different indications (on-demand, surgery, and prophylaxis) as measured by EUHASS.</measure>
    <time_frame>2 years</time_frame>
    <description>Number of adverse events as measured by EUHASS as well as treatment-emergent side effects of therapy for various Von Willebrand Factor (VWF) regimens for different indications (on-demand, surgery and prophylaxis) in adult and pediatric participants with clinically severe congenital VWD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Enrich and analyze data collected about AE events as defined by EUHASS using standardized diagnostic battery using an ELISA-based VWF assay.</measure>
    <time_frame>3 years</time_frame>
    <description>To enrich and analyze the data from currently enrolled participants with clinically severe congenital VWD in the ATHNdataset via the collection of laboratory data consisting of a standardized diagnostic battery using an ELISA-based VWF assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enrich and analyze data collected about AE events, as defined by EUHASS using genetic sequence analysis of VWF coding regions and adjacent non-coding regions.</measure>
    <time_frame>2 years</time_frame>
    <description>To enrich and analyze the data from currently enrolled participants with clinically-severe congenital VWD in the ATHNdataset via the collection of laboratory data using genetic sequence analysis of VWF coding regions and adjacent non-coding regions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substudy modules will be developed to evaluate and report on cohorts of study participants who initiate treatment with specific product.</measure>
    <time_frame>2 years</time_frame>
    <description>To measure the number of participants taking unique VWF products.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factor replacement used as prophylaxis.</measure>
    <time_frame>3 years</time_frame>
    <description>Report number of particpants using factor replacement as prophylaxis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Capture bleeding events using the Pictorial Bleeding. Assessment Chart.</measure>
    <time_frame>3 years</time_frame>
    <description>The number of participants with bleeding events analyzed over the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Capture annualized bleeding rate (ABR) using ISTH BAT Assessment Tool.</measure>
    <time_frame>3 years</time_frame>
    <description>The change in the annualized bleeding rate (ABR) for participants over the course of the study by analyzing the number of bleeding events divided by the length of time of the treatment (in years).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculate the effectiveness of VWD treatment as measured by health care utilization.</measure>
    <time_frame>3 years</time_frame>
    <description>The number of visits/hospitalizations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyze the effectivness of VWD treatment as measured by score on PROMIS questionnaire using the 7 PROMIS domains (depression; anxiety; physical function; pain; fatigue; sleep disturbance; and participation in social roles and activities).</measure>
    <time_frame>3 years</time_frame>
    <description>Health-related Quality of Life measured annually by the Patient Reported Outcomes Measurement Information System (PROMIS ®) Profile.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Capture bleeding events using the Pictorial Bleeding Assessment Chart.</measure>
    <time_frame>3 years</time_frame>
    <description>The number of participants with bleeding events analyzed over the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Capture annualized bleeding rates (ABR) using the Pictorial Bleeding Assessment Chart.</measure>
    <time_frame>3 years</time_frame>
    <description>The change in the annualized bleeding rate (ABR) for participants over the course of the study by analyzing the number of bleeding events divided by the length of time of the treatment (in years).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculate the success of VWD treatment as measured by health care utilization.</measure>
    <time_frame>3 years</time_frame>
    <description>The types of visits/hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Capture the effectiveness of VWD treatments using health-related quality of life.</measure>
    <time_frame>3 years</time_frame>
    <description>Measure walking ability as part of quality of life using the V-WIQ questionnaire.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Von Willebrand Diseases</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      All participants will undergo laboratory evaluation. The remaining specimen volume will be
      stored and may be used for future research.

      Specimens will be tested as follows:

        -  FVIII Activity, VWF Antigen, and the VWF:GPIbM Activity Assay. Reflex testing may
           include: VWD Type 2B Binding, VWD Type 2N Binding, VWF Propeptide Antigen, and/or VWF
           Quantitative Multimers

        -  Genetic sequence analysis of VWF coding regions and adjacent non-coding regions
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This is a natural history study in which it is anticipated that approximately 130
        participants will be enrolled. The study will attempt to enroll a target number of at least
        30 participants who are receiving VONVENDI but will not mandate the use of VONVENDI.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants with severe Von Willebrand Disease with Type 3 VWD or VWF:RCo, VWF:GPlbM
             or VWF:Ag ≤30% of pooled normal control plasma on more than one occasion;

          2. Participants with clinically severe VWD as defined by VWF:RCo, VWF:GPlbM or VWF:Ag
             ≤40% of normal with severe bleeding phenotype defined as requiring recurrent use of
             factor concentrates; and

          3. Co-enrollment in the ATHNdataset.

        Exclusion Criteria:

          1. Diagnosis of platelet-type VWD;

          2. Diagnosis of acquired VWD (clinical diagnosis based on association with
             hypothyroidism, lymphoproliferative and myeloproliferative disorders, malignancies and
             cardiovascular disease, typically aortic stenosis or LVAD).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Robert Sidonio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University / Children's Healthcare of Atlanta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angela Weyand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Hemophilia and Coagulation Disorders</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carol Fedor</last_name>
    <phone>1-800-360-2846</phone>
    <email>cfedor@athn.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nikki Hirsh, MS</last_name>
    <phone>1-800-360-2846</phone>
    <email>nhirsh@athn.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Inherited Blood Disorders</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Nugent, MD</last_name>
      <email>dnugent@c3dibd.org</email>
    </contact>
    <investigator>
      <last_name>Diane Nugent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Regents of the UC San Diego, Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Limjoco</last_name>
      <email>jlimjoco1@rchsd.org</email>
    </contact>
    <investigator>
      <last_name>Courtney Thornburg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver Hemophilia and Thrombosis Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Kula</last_name>
      <phone>303-724-0363</phone>
      <email>Kristi.Norton@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>Molly Brown</last_name>
      <phone>303 724-0363</phone>
      <email>molly.a.brown@ucdenver.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Bleeding and Clotting Disorders Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Boruchov, MD</last_name>
      <phone>860-679-2100</phone>
      <email>dboruchov@connecticutchidrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Mary Banevicius</last_name>
      <email>Mbanevicius@connecticutchildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Donna Boruchov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida Hemophilia Treatment Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Mercado</last_name>
      <email>rebeccahmercado@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Tung Wynn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta/Emory</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Roberts</last_name>
      <phone>404-727-9698</phone>
      <email>kristin.roberts@choa.org</email>
    </contact>
    <contact_backup>
      <last_name>Gladys Lee</last_name>
      <phone>404 727 9698</phone>
      <email>gladys.lee@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Sidonio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shannon Meeks, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Glaivy Batsuli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carolyn Bennett, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bleeding and Clotting Disorders Institute</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Gonzales</last_name>
      <phone>309-692-5337</phone>
      <phone_ext>135</phone_ext>
      <email>sarah@ilbcdi.org</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Taggert</last_name>
      <phone>309 692 5337</phone>
      <email>elizabetht@ilbcdi.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Tarantino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathon Roberts, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana Hemophilia and Thrombosis Center (IHTC)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tasia Weiss</last_name>
      <phone>317-871-0011</phone>
      <phone_ext>289</phone_ext>
      <email>nweiss@ihtc.org</email>
    </contact>
    <contact_backup>
      <last_name>Kat Molitor</last_name>
      <phone>317 871 0011</phone>
      <phone_ext>287</phone_ext>
      <email>kmolitor@ihtc.og</email>
    </contact_backup>
    <investigator>
      <last_name>Amy Shapiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana Center for Bleeding and Clotting Disorders</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melody Benton</last_name>
      <phone>504-988-3596</phone>
      <email>mbenton@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Tamuella Singleton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hemophilia and Coagulation Disorders</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Hauke</last_name>
      <email>haukerl@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kaitlyn Marshall</last_name>
      <email>mcnultk@med.umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Angela Weyand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan Hemostasis and Thrombosis Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan Hannan</last_name>
      <email>bhannan@med.wayne.edu</email>
    </contact>
    <contact_backup>
      <last_name>Takyra Stanton</last_name>
      <email>TStanton2@dmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Madhvi Rajpurkar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan State University Center for Bleeding and Clotting Disorders</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48823</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Robinson, RN</last_name>
      <email>AnnaRN@msu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julie Rose, RN</last_name>
      <phone>517 353 9385</phone>
      <email>julie.rose@@hc.msu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Roshni Kulkarni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renuka Gera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diane MacDonald, MD, FACP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ajovi Scott-Emuakpor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aghad Chamdin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Santosh Hammond, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Carlson, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University Center for Treatment of Bleeding and Blood Clotting Disorders</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Pardeshi</last_name>
      <email>spardeshi@dom.wstl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Naumann</last_name>
      <email>snaumann@dom.wstl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Elaine Majurus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Comprehensive Hemophilia and Thrombosis Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Debra Ornstein, MD</last_name>
      <phone>603-650-5486</phone>
      <email>deborah.l.ornstein@hitchcock.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charmaine Biega</last_name>
      <email>Charmaine.Biega@nationwidechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Linda Casto</last_name>
      <email>linda.casto@nationwidechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Amy Dunn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>91239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Haley, MD</last_name>
      <phone>503-494-8716</phone>
      <email>haley@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Comprehensive Hemophilia and Thrombophilia Program / Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Panercki</last_name>
      <phone>215-614-0506</phone>
      <email>Karen.Panckeri@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Kelty, RN</last_name>
      <phone>215-614-0506</phone>
      <email>Mary.Kelty@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam Cuker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elaine Chiang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susan Yeck, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dyanne Morris, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hemostasis &amp; Thrombosis Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin Montcrieff, RN</last_name>
      <phone>401-444-8250</phone>
      <email>cmontcrieff@lifespan.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Palmetto Health Richland</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Jones</last_name>
      <email>robin.jones@palmettohealth.org</email>
    </contact>
    <investigator>
      <last_name>Stuart Cramer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee, University Clinical Health (Memphis)</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandeep Rajan, MD</last_name>
      <phone>901-866-8547</phone>
      <email>srajan2@uthsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pamela Krueger</last_name>
      <email>pamela.krueger@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Alexandra Borst, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hemophilia Outreach Center</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54311</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ken Friedman, MD</last_name>
      <phone>920-965-0606</phone>
      <email>Kenneth.friedman@bcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sumedha Ghate</last_name>
      <email>sumedhag@hocgb.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ken Friedman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Versiti - Blood Center of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Stephany</last_name>
      <phone>414-257-2424</phone>
      <email>karen.stephany@bcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Megan Lemancyzk</last_name>
      <phone>414 257 2424</phone>
      <email>megan.lemancyzk@bcw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lynn Malec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shawn Jobe, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ken Friedman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 11, 2019</study_first_submitted>
  <study_first_submitted_qc>February 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VWF</keyword>
  <keyword>von Willebrand Disease</keyword>
  <keyword>VWD</keyword>
  <keyword>Factor</keyword>
  <keyword>ATHN 9</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Von Willebrand Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

